logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9623015 B1

PDFFull Text
Date of Patent:
Apr. 18, 2017

Filed:

Nov. 05, 2013

Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse

Applicant:

Commissariat À L'energie Atomique ET Aux Energies Alternatives (Cea), Paris, FR;

Inventors:

Stéphane Prost, Malabry, FR;

Marek Kirszenbaum, Vanves, FR;

Mikael Le Dantec, Paris, FR;

Philippe Rousselot, Paris, FR;

Philippe Leboulch, Charlestown, MA (US);

Assignee:

Commissariat à L'Energie Atomique et aux Energies Alternatives (CEA), Paris, FR;

Attorneys:

Nelson Mullins Riley & Scarborough LLP

Jane E. Remillard, Esq.

Cynthia L. Kanik

Primary Examiner:

Yong Chu

Int. Cl.
CPC ...
A61K 31/4439 (2006.01); A61K 31/506 (2006.01); A61K 45/06 (2006.01); A61K 31/404 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/496 (2006.01); A61K 31/5025 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 31/404 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01);
Abstract

Provided are methods for eliminating hematologic cancer stem cells in vivo, and thus preventing cancer relapse. The methods comprise a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist (e.g., a PPARγ agonist) after the patient has had ana initial course of treatment with an anti-cancer agent (e.g., a TKI), to eliminate residual cancer stem cells which cause relapse.

Find Patent Forward Citations

Prost, Stéphane. (2017). Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse (U.S. Patent No. 9623015). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/9623015

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…